Mechanisms of action of glatiramer acetate in multiple sclerosis.
about
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot studyGlatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of actionFebrile illness and pro-inflammatory cytokines are associated with lower neurodevelopmental scores in Bangladeshi infants living in poverty.Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.Childhood multiple sclerosis: a review.Glatiramer acetate: evidence for a dual mechanism of action.Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice.T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works.Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor.Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.Drug Insight: using statins to treat neuroinflammatory disease.Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate.Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosisInflammation and therapeutic vaccination in CNS diseases.Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.Structure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis.Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitisDisease Modifying Potential of Glatiramer Acetate in Huntington's DiseaseEquivalent Gene Expression Profiles between Glatopa™ and Copaxone®.Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance.Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.What do we know about the mechanism of action of disease-modifying treatments in MS?Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.Treatment of children and adolescents with multiple sclerosis.Glatiramer acetate in multiple sclerosis.Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.Polymeric drugs: Advances in the development of pharmacologically active polymers.Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.Evidence for humoral autoimmunity in neuromyelitis optica.Glatiramer acetate therapy for multiple sclerosis: a review.Glatiramer in the treatment of multiple sclerosisMechanism of action of glatiramer acetate in treatment of multiple sclerosis.Statins--treatment option for central nervous system autoimmune disease?Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.
P2860
Q21034132-71079B18-8A2B-428B-AEB8-9343B10C2B4BQ28308287-F2E29B22-7CBD-4E6C-BE7C-81D5AD7CDD3BQ30414660-71C1EB8E-1862-4389-8039-16369B7F1454Q31014036-BB6CB50E-8B82-4415-8794-5046C4C52E3EQ31047410-1071DF8E-E94A-4D18-9D9B-DB65C9C2F2F7Q33345291-428A4B72-BF89-4F06-8F23-524645B21F24Q33354106-E260A39B-13A0-41CD-82F5-C4A6E1DE36E4Q33723154-9D64BFA8-9F37-49FE-8109-45DE6389E845Q33772149-3624D031-8E4C-4C56-9C8D-76DA5DA57F8BQ33960392-0EDAC436-9150-49E2-8D39-DBE32DC5EC12Q34070020-188A80FB-83DA-46B4-95BB-BFF6102D8022Q34223767-B104942A-246C-4FF9-9E39-BEF91CCB13EFQ34560503-3E9A2C6D-C7DD-4F7B-8E55-EE20CDE528CDQ34567725-A5D7E06A-82DF-4D1F-A630-27EE663A1229Q34705686-57F3ECD9-85A8-4E27-B756-E7E4DA3F54FFQ34789216-70C6C93B-279C-4FFF-9E9B-EA48EA20D3BBQ35030005-52992A55-1AD8-424A-AB6A-E9F2C7C94783Q35088106-AA05FEF6-6148-411A-B509-356A5722C67FQ35318199-F07AF764-505A-449C-99DA-6D5FE88D6439Q35571156-7950CB77-C076-43F9-B983-62F02E24EA8DQ35782283-1C2D582F-C4F8-4C9F-8E7E-C0641E9A96BCQ35810306-5602EC7C-A0EB-4EFA-A974-10EB82648650Q35839611-DD033BC7-2FD2-4289-954D-7746ED2BB3ACQ35861182-41C3DCF7-5B40-4736-8359-4D7413CD4918Q35953300-8A32242E-EFB0-42D4-8381-B75EC0F40A30Q36153387-62B4862F-3728-4DAB-BF15-B3123237A16DQ36153390-E25D1C34-997D-481E-BC0C-3B581EB369E5Q36198583-EB047087-8384-43AE-A111-056C2AB5A29EQ36290143-82C64AAA-6F1B-4B74-B387-6095259153D8Q36299405-ABFF5A87-0BA3-4E71-BC61-DEA6C628B579Q36307604-4864D6A3-42FC-4B72-9365-CB56EFC51C30Q36353053-8BEBD274-ABE8-408D-988A-07E139E9E0DEQ36419566-0E448982-11DA-4E1A-BD84-30BA1C7DFEB9Q36474367-C3D29179-CED5-492C-BDEF-10F009F4085AQ36662903-6966E677-A80B-460F-A541-E95571BF4C56Q36918770-E9115824-CE4A-4D16-B887-84A1E5437B9BQ36963184-A1BB985D-9AD1-48E6-9DA4-4ACC081B6143Q36963213-E057AF6E-0AC2-46DF-A36D-1AAAD5887929Q37001036-99A2F627-AA3F-41C2-BCD8-B75A92393C9DQ37114231-8137F509-2A1E-45A2-AC86-9AA85C2A3C6C
P2860
Mechanisms of action of glatiramer acetate in multiple sclerosis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Mechanisms of action of glatiramer acetate in multiple sclerosis.
@en
Mechanisms of action of glatiramer acetate in multiple sclerosis.
@nl
type
label
Mechanisms of action of glatiramer acetate in multiple sclerosis.
@en
Mechanisms of action of glatiramer acetate in multiple sclerosis.
@nl
prefLabel
Mechanisms of action of glatiramer acetate in multiple sclerosis.
@en
Mechanisms of action of glatiramer acetate in multiple sclerosis.
@nl
P2093
P356
P1433
P1476
Mechanisms of action of glatiramer acetate in multiple sclerosis.
@en
P2093
P304
P356
10.1212/WNL.56.6.702
P407
P577
2001-03-01T00:00:00Z